Adjuvant ab interno tumour treatment after proton beam irradiation- Adjuvant surgery and its effect on secondary enucleation

Session Details

Session Title: Free Paper Session 15: Mixed Session

Session Date/Time: Friday 08/09/2017 | 16:30-18:00

Paper Time: 16:36

Venue: Room 117

First Author: : I.Seibel GERMANY

Co Author(s): :    A. Riechardt   J. Heufelder   D. Cordini   A. Joussen                    

Abstract Details


This study was performed to show long-term outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with the main focus on outcomes according to different adjuvant ab interno surgical procedures.


Retrospective cohort study


All patients treated with primary proton beam therapy for choroidal or ciliary body melanoma between June 1998 and June 2015 were included.


A total of 2499 patients underwent primary proton beam therapy, with local tumour control and globe preservation rates of 95.9% and 94.8% after 5 years, respectively. A total of 110 (4.4%) patients required secondary enucleation. Unresponsive neovascular glaucoma was the leading cause of secondary enucleation in 78 patients (3.1% of 2499 patients). The 5 year enucleation-free survival rate was 94.8% in the endoresection group, 94.3% in the endodrainage group and 93.5% in the comparator group. The log rank test showed p=0.014 (comparator group versus endoresection group), and p=0.06 (comparator group versus endodrainage-vitrectomy group). Patients treated with endoresection or endodrainage-vitrectomy developed less radiation retinopathy (30.5% and 37.4% after 5 years, p=0.001 and p=0.048 (Kaplan Meier), respectively) and less neovascular glaucoma (11.6% and 21.3% after 5 years, p=0.001 and 0.01 (Kaplan Meier), respectively) compared with the comparator group (52.3% radiation retinopathy and 57.8% neovascular glaucoma after 5 years).


This study suggests that in larger tumours the enucleation and neovascular glaucoma rates might be reduced by adjuvant surgical procedures. Although endoresection is the most promising adjuvant treatment option, the endodrainage-vitrectomy is recommended in patients who are ineligible for endoresection.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy